




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |  |                             |   |
|---|--|-----------------------------|---|
| (51) International Patent Classification <sup>6</sup> : |  | A1                          | (11) International Publication Number: <b>WO 99/12560</b>   |
| <b>A61K 38/18, C12N 5/06, 5/08</b>                      |  |                             | (43) International Publication Date: 18 March 1999 (18.03.99)   |
| (21) International Application Number:                  | PCT/US98/18772   |                             | (81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).   |
| (22) International Filing Date:                         | 9 September 1998 (09.09.98)  |                             |   |
| (30) Priority Data:                                     | 60/058,258   | 9 September 1997 (09.09.97) | US  |
| (71) Applicant (for all designated States except US):   | CREATIVE BIOMOLECULES, INC. [US/US]; 45 South Street, Hopkinton, MA 01748 (US).  |                             |   |
| (72) Inventors; and                                     |  |                             | <b>Published</b>  |
| (75) Inventors/Applicants (for US only):                | RUEGER, David, C. [US/US]; 81 Pine Hill Road, Southborough, MA 01772 (US). CHARETTE, Marc, F. [US/US]; 17 Ellicott Street, Needham, MA 02192 (US). EBENDAL, Ted [SE/SE]; Uppsala University, Dept. of Neurological Sciences, P.O. Box 587, BMC, S-751 23 Uppsala (SE). |                             | <i>With international search report.<br/>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (74) Agent:   | TWOMEY, Michael, J.; Testa, Hurwitz & Thibeault, LLP, High Street Tower, 125 High Street, Boston, MA 02110 (US).   |                             |   |

(54) Title: SYNERGISTIC EFFECTS OF OP/BMP MORPHOGENS AND GDNF/NGF NEUROTROPHIC FACTORS



## (57) Abstract

A synergistic effect of OP/BMP morphogens in combination with GDNF/NGF neurotrophic factors in promoting the survival or growth, or inhibiting the death or degeneration, of mammalian cells, particularly neural cells, which express OP/BMP-activated serine/threonine kinase receptors and GDNF/NGF-activated tyrosine kinase receptors, is disclosed. Also disclosed are new methods for the *in vivo* and *in vitro* treatment of such cells, including *in vivo* treatments for mammals afflicted with, or at imminent risk of, damage or injury to such cells, as well as new pharmaceutical preparations for such *in vivo* and *in vitro* treatments.